Alphyn is developing Zabalafin Hydrogel as the first therapy to simultaneously tackle the interconnected drivers of AD
The U.S. oncology market is projected to soar from $81 billion in 2025 to $212 billion by 2034
The companies aim to expand treatment options for millions living with metabolic disorders
Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas
The patented product, developed by Venus Medicine Research Centre (VMRC) for the treatment of multidrug-resistant (MDR) infections, was sold to Cipla in 2019
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
DUPLEX’s two-compartment, PVC- and DEHP-free design keeps medication and diluent separate until activation
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
Subscribe To Our Newsletter & Stay Updated
